Lestaurtinib

From Self-sufficiency
Jump to: navigation, search
Lestaurtinib
File:Lestaurtinib.png
Identifiers
ATC code none
PubChem CID 126565
Chemical data
Formula C26H21N3O4
Molar mass 439.462 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3[1], JAK2[2], TrkA, TrkB and TrkC.[3]

Uses

It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). "Lestaurtinib". Drugs of the Future. 32 (3): 215. doi:10.1358/dof.2007.032.03.1084137. 
  4. Cephalon - Pipeline